NCT02096510View on ClinicalTrials.gov

Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 27, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Addison DiseaseAdrenal Hyperplasia Congenital
Interventions
DRUG

Solu-Cortef

administration by pump for minimum 2 weeks

DRUG

Cortef

tablet treatment 2 ro 3 times per day for 14 days

Trial Locations (1)

5021

University Hospital Helse Bergen, Bergen

All Listed Sponsors
lead

Haukeland University Hospital

OTHER

NCT02096510 - Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia | Biotech Hunter | Biotech Hunter